Pantoprazol Stada (Pantoprazole)

Pantoprazol Stada is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related disorders:

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis.
• Erosive gastritis and duodenal ulcer disease: accelerates the healing of ulcer lesions.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare endocrine disorder.
• Prevention of NSA‑induced gastroduodenal ulcers: reduces the risk of ulcer formation in patients requiring long‑term NSAID therapy.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump in its active state, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduced acidity in the stomach lumen.

Pantoprazol Stada is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reactions (anaphylaxis, angio‑edema).
• Clostridioides difficile‑associated colitis.
• Acute interstitial nephritis.
• Low magnesium levels (hypomagnesemia) with prolonged use.
• Fractures of the hip, wrist or spine with long‑term therapy.
• Liver enzyme elevations indicating possible hepatic injury.

Before initiating therapy, consider the following precautions:

• Renal impairment: adjust dose in severe kidney disease.
• Hepatic impairment: use with caution in moderate to severe liver dysfunction.
• Elderly patients: monitor for dehydration and electrolyte disturbances.
• Concomitant use of drugs that increase gastric pH: assess need for dose adjustment.
• Long‑term therapy: evaluate bone health and magnesium status periodically.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR; monitor coagulation parameters.
• Methotrexate: reduced renal clearance may raise serum levels.
• Digoxin: slight increase in serum concentration; observe for toxicity signs.